TermGallery
Inglês
Inglês
Espanhol
Catalão
Português
Russo
PT
English
Español
Català
Português
Русский
1
Therapy was continued until evidence of disease progression or
unacceptable
toxicity
occurred.
2
Treatment was stopped early in both arms for progressive disease or
unacceptable
toxicity
.
3
Patients received oral ibrutinib 420 mg once daily until progression or
unacceptable
toxicity
.
4
Patients continued receiving sorafenib until disease progression or
unacceptable
toxicity
occurred.
5
There were no treatment-related deaths and no patient encountered
unacceptable
toxicity
.
6
Treatment cycles were repeated until disease progression, patient's refusal or
unacceptable
toxicity
occurred.
7
Treatment continued until there was documented disease progression or
unacceptable
toxicity
.
8
Cycles were repeated until disease progression,
unacceptable
toxicity
or patient refusal.
9
The 28-day cycle was repeated until there was
unacceptable
toxicity
or disease progression.
10
Pertuzumab and trastuzumab were administered until disease progression or
unacceptable
toxicity
.
11
Treatment was continued until disease progression or
unacceptable
toxicity
for up to 12 months.
12
Treatment was continued until progression,
unacceptable
toxicity
,
or patient refusal.
13
Treatment was continued until disease progression or
unacceptable
toxicity
occurred.
14
Patients remained on study until disease progression or
unacceptable
toxicity
.
15
Treatment was repeated until disease progression or
unacceptable
toxicity
occurred.
16
Treatment continued until disease progression by RECIST or
unacceptable
toxicity
.
unacceptable
toxicity
unacceptable